ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| Net Income | -$9 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EPS Diluted | -8.48 | -1,089.66 | -930.25 | -173.66 |
| % Growth | 99.2% | -17.1% | -435.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |